Q-omics provides the consensus-scored NDUFV3 profile across patient tissues and cancer cell-line models. NDUFV3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NDUFV3 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, NDUFV3 RNA expression shows 17,470 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, LIHC, and ACC as cancer lineages where NDUFV3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFV3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFV3 survival associations across molecular data types. NDUFV3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFV3 RNA expression–survival associations across cancer types. High NDUFV3 expression shows unfavorable associations in UVM, ACC, COAD, LGG, HNSC and STAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NDUFV3 RNA expression.
This table summarizes NDUFV3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFV3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFV3 shows lower tumor expression in THCA, KICH and KIRP and higher tumor expression in LIHC, LUAD and CHOL. The LIHC box plot shows higher NDUFV3 RNA expression in tumor versus normal tissue (log2 FC = +0.701, t-test p < 0.001).
This table shows molecular features associated with NDUFV3 in patient tissues and cancer cell lines. In patient samples, NDUFV3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFV3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SOFT_TISSUE.
